Live, Attenuated Mumps-Virus Vaccine

Publisher Website
Google Scholar
Abstract
Jeryl-Lynn strain (B level) live, attenuated mumps-virus vaccine was administered to 6283 initially susceptible children and 163 adults, including 132 males. There was no evident clinical reaction to the vaccine either in adults or in children including infants. The overall seroconversion rate was 96.9 per cent for children and 92.6 per cent for adults. The protective efficacy shown on natural mumps challenge was of the order of 95 per cent, and such protection was shown to last for at least 20 months. The neutralizing antibody induced by the vaccine persisted for at least two years without substantial decline and the pattern closely resembled that for antibody persistence after naturally acquired mumps. The vaccine could be coadministered with live measles vaccine, with satisfactory responses to both.